Different platinum-resistant BRCA1 methylated models show significant BRCA1 gene expression, associated with a low percentage of BRCA1 methylation and increased levels of RAD51 foci upon cisplatin treatment, supporting incomplete promoter methylation as potential mechanism of platinum resistance in these tumours. The gene discussed is RAD51; the disease is neoplasm.